Search Results 1531-1540 of 16067 for Epilepsy (Partial Onset)

  1. #MayoClinicRadio podcast: 9/29/18 - Mayo Clinic News Network

    Jamie Van Gompel, a neurosurgeon at Mayo Clinic, explains how deep brain stimulation is being used to control seizures for some epilepsy patients. And Dr ...

  2. Safety and Tolerability of GTX-104 Compared With Oral Nimodipine in Patients With aSAH - Mayo Clinic

    Able to start IP within 96 hours from the onset of aSAH. Note 1: The onset of aSAH is defined as the time when the subject experienced the first symptom of ...

  3. Publications - R John Presutti, D.O., FAAFP - Mayo Clinic

    ... onset diabetes. Prev Med Rep. 2023 Feb; 31:102110 Epub 2023 Jan 16. View PubMed; Pujalte GGA, Costa LMC, Clapp AD, Presutti RJ, Sluzevich JC. More Than Skin ...

  4. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

    Activated partial thromboplastin (aPTT) and prothrombin time (PT) ≤1.5 ... duration of study participation and for at least 30 days after the last ...

  5. Pediatrics Clinical Trials - Medical Professionals

    The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer ...

  6. Computer Vision-based Assessment of Upper Extremity Motor Function in Stroke Patients - Mayo Clinic

    History of seizures; History of musculoskeletal impairment affecting upper extremity strength or range of motion; History of CNS malignancy. Participating Mayo ...

  7. EEG Cap for Identification of Non-Convulsive Status Epilepticus - Mayo Clinic

    NCSE becomes more refractory to treatment after one hour of seizure activity, making rapid identification and treatment of NCSE of great clinical importance.

  8. Headache: First aid - Mayo Clinic

    Happens with seizures. Immediate medical attention also is needed if your headache occurs with new: Dizziness or loss of balance. Weakness or paralysis ...

  9. A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome - Mayo Clinic

    The participant is willing to abstain from application of a non-study topical medication (prescription or over the counter) to facial skin for the duration of ...

  10. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

    The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the ...